Parkman Healthcare Partners LLC cut its holdings in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 10.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 116,138 shares of the company's stock after selling 14,111 shares during the quarter. Parkman Healthcare Partners LLC owned approximately 0.09% of Vaxcyte worth $9,507,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wells Fargo & Company MN increased its position in Vaxcyte by 53.7% in the fourth quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock worth $5,916,000 after purchasing an additional 25,257 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Vaxcyte by 23.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company's stock worth $2,163,000 after acquiring an additional 4,962 shares in the last quarter. TimesSquare Capital Management LLC lifted its holdings in Vaxcyte by 53.7% during the fourth quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company's stock worth $33,860,000 after acquiring an additional 144,516 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Vaxcyte by 70.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company's stock worth $49,418,000 after acquiring an additional 246,049 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its position in shares of Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock valued at $33,000 after purchasing an additional 260 shares during the period. 96.78% of the stock is currently owned by institutional investors and hedge funds.
Vaxcyte Stock Performance
Shares of Vaxcyte stock traded up $0.25 on Monday, reaching $32.10. 669,768 shares of the company's stock were exchanged, compared to its average volume of 1,335,848. The company has a market capitalization of $4.14 billion, a P/E ratio of -6.98 and a beta of 1.27. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $121.06. The firm's 50-day moving average is $42.56 and its two-hundred day moving average is $71.47.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02). During the same period in the prior year, the company posted ($0.85) earnings per share. On average, analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.
Insider Buying and Selling
In other news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $73.27, for a total transaction of $586,160.00. Following the completion of the sale, the chief operating officer now owns 154,931 shares in the company, valued at approximately $11,351,794.37. This trade represents a 4.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.10% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on PCVX. Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Cantor Fitzgerald initiated coverage on Vaxcyte in a research note on Tuesday, April 22nd. They issued an "overweight" rating on the stock. The Goldman Sachs Group lowered their price objective on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Bank of America lowered their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Finally, Needham & Company LLC reiterated a "buy" rating and set a $90.00 price objective on shares of Vaxcyte in a research report on Tuesday, April 8th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average target price of $136.50.
Check Out Our Latest Report on PCVX
About Vaxcyte
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
See Also
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
